Status:

RECRUITING

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Lead Sponsor:

Shengjing Hospital

Conditions:

Breast Cancer

Eligibility:

FEMALE

18-70 years

Phase:

PHASE3

Brief Summary

Triple-negative breast cancer (TNBC) accounts for about 20% of clinical breast cancer. Clinical characteristics include early onset, high malignancy and heterogeneity. There is no effective drug targe...

Detailed Description

Breast cancer has been one of the most common malignant tumors with highest morbidity and mortality that threatens women's health worldwide. Among US women, there were 250,000 new invasive breast canc...

Eligibility Criteria

Inclusion

  • breast cancer is confirmed by the mammography, and the immunohistochemical results of cancer tissues are negative for estrogen receptor, progesterone receptor and anti-human epidermal growth factor receptor 2;
  • positive for axillary lymph node metastasis;
  • 18-70 years of age, female;
  • patients have good compliance with the planned treatment, who are volunteer to participate in the study, are willing to be treated with solvent-based paclitaxel or nab-P at random, and provide written informed consent with the premise of fully understanding the study protocol.

Exclusion

  • pregnant and lactating women;
  • distant metastasis;
  • patients with a history of other cancers or who have received radiotherapy on the chest;
  • abnormalities in blood tests or presence of other symptoms of infection;
  • allergy to paclitaxel;
  • patients who have psychotropic drug abuse until now or those with a history of mental disorders;
  • abnormalities in important organs such as the heart, lung, liver and kidney;
  • patients who have participated in other clinical trials.

Key Trial Info

Start Date :

July 19 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2026

Estimated Enrollment :

1498 Patients enrolled

Trial Details

Trial ID

NCT04137653

Start Date

July 19 2021

End Date

November 30 2026

Last Update

July 20 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China, 110004